[artículo] 
inThe Journal of Clinical Psychiatry > Año 2019 - Vol. 80 - No.1 (Enero - Febrero) . - pp. 45-50

Título :	Early Placebo Improvement Is a Marker for Subsequent Placebo Response in Long-Acting Injectable Antipsychotic Trials for Schizophrenia : Combined Analysis of 4 RCTs
Tipo de documento:	texto impreso
Autores:	Fumiaki Kumagai, Autor ; Takefumi Suzuki, Autor ; Wolfgang Fleischhacker, Autor
Fecha de publicación:	2019
Artículo en la página:	pp. 45-50
Idioma :	Inglés (eng)
Palabras clave:	Antipsicotico inyectable + placebo, Esquizofrenia.
Resumen:	Placebo effects remain largely unexplored in clinical trials of long-acting injectable (LAI) antipsychotics for schizophrenia. This study aims to characterize patients showing improvements after placebo injections and to search for criteria for the prediction of subsequent response based on the magnitude of score changes after the first week of treatment.
Link:	./index.php?lvl=notice_display&id=20477

[artículo] Early Placebo Improvement Is a Marker for Subsequent Placebo Response in Long-Acting Injectable Antipsychotic Trials for Schizophrenia : Combined Analysis of 4 RCTs [texto impreso] / Fumiaki Kumagai, Autor ; Takefumi Suzuki, Autor ; Wolfgang Fleischhacker, Autor . - 2019 . - pp. 45-50.
Idioma : Inglés (eng)
in The Journal of Clinical Psychiatry > Año 2019 - Vol. 80 - No.1 (Enero - Febrero) . - pp. 45-50

Palabras clave:	Antipsicotico inyectable + placebo, Esquizofrenia.
Resumen:	Placebo effects remain largely unexplored in clinical trials of long-acting injectable (LAI) antipsychotics for schizophrenia. This study aims to characterize patients showing improvements after placebo injections and to search for criteria for the prediction of subsequent response based on the magnitude of score changes after the first week of treatment.
Link:	./index.php?lvl=notice_display&id=20477